Welcome to NanoPin Technologies Inc.
Our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious disease epidemics such as tuberculosis (historically the leading cause of death from infectious disease worldwide), HIV, and COVID-19. 

Tuberculosis (TB) remains the "Top Infectious Disease Killer Worldwide" according to the World Health Organization with an estimated 1.5 million deaths and 10 million new cases every year.  HIV has claimed over 32 million lives and the WHO estimates 37.9 million people are currently living with the disease.  With ever growing global connectivity, the threat of infectious diseases and future contagions require better, more advanced detection technologies to provide much needed new tools for our healthcare providers.  
​

Rapid Detection of Active Disease

NanoPin assays can detect extremely low levels of active disease elements (antigen peptides) in blood samples.  This is a critical differentiator with other diagnostic assays which can not distinguish between latent and active disease. 
​

Detection in Multiple Populations

NanoPin's technology can readily detect infectious disease in a wide range of patient populations.  In the example of tuberculosis, our technology is able to accurate detect TB in not only adult populations but also chidren and infants and immunocomprised patient group such as those with HIV co-infection.  ​

Proprietary Solutions

NanoPin has proprietary intellectual property for its diagnostic platform, methods, and applications.  We are committed to enhancing our IP as we work with our partners to provide advanced diagnostic assays in the USA and globally.  ​

Versatile Platform

Our sensitive and accurate diagnostic platform is capable of detecting both known diseases such as TB and HIV and can be a future rapid response platform for future contagions.  The platform can be adapted to future disease markers in blood for novel disease applications.​
Infectious disease kills ~15 million people each year.  This includes more recent diseases (HIV, Ebola) and ancient diseases (TB, Malaria, Cholera). Growing resistance to antibiotics and drug resistance disease strains is making it harder to combat infectious diseases. ​

Advancing Diagnostics for Improved Patient Care

NanoPin thrives in an entrepreneurial work environment to pursue an innovative and partner-driven approach that allows our team to work collaboratively on cutting-edge clinical applications with the potential to significantly impact patient health.
. 
 Picture

​



​